---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-145019"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:41:03.498470+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD Q1 net loss narrows to $2.3M from $17.9M; continuing ops loss $0.24/share

## Summary
- Net loss from continuing operations $2.3M ($0.24/share) vs $17.9M ($2.08) in Q1 2022.
- License and service revenues $0.4M, down from $0.7M due to transition to royalty-based business.
- Total operating expenses fell 82.8% to $3.1M, reflecting business transformation and reduced infrastructure.
- Net loss from discontinued ops $1.3M ($0.13/share) vs $31.1M ($3.62), as wind-down continues.

## SEC filing metadata
- accession: 0001193125-23-145019
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000119312523145019/0001193125-23-145019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000119312523145019/d481253d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-145019
- JSON: https://secwatch.observer/filing/0001193125-23-145019.json
- Plain text: https://secwatch.observer/filing/0001193125-23-145019.txt

## Key facts
- Earnings Releases
  TherapeuticsMD, Inc. reported first quarter ended March 31, 2023 results: revenue $0.4 million, net income $2.3 million, EPS $0.24 per basic and diluted common share.
  - Period: first quarter ended March 31, 2023
  - Revenue: $0.4 million
  - Net income: $2.3 million
  - EPS: $0.24 per basic and diluted common share
  - Result: reported results
  source text: Net loss from continuing operations was $2.3 million for the quarter ended March 31, 2023, or $0.24 per basic and diluted common share, compared to a net loss from continuing operations of $17.9 million, or $2.08 per basic and diluted common share, for the comparable period in 2022. License and Service Revenues from Continuing Operations • License and service revenues from continuing operations, which are revenues related to license agreements, were $0.4 million for the quarter ended March 31, 2023, compared to $0.7 million in license and service revenue related to sales to other licensees for the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000119312523145019/0001193125-23-145019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.